Production calculations of 166Dy/166Ho in vivo generator through neutron irradiation in Tehran Research Reactor (TRR)

Authors

Abstract

Holmium-166 is one of the most effective radionuclides used for treatment of bone marrow cancer and rheumatoid arthritis. Using 166Dy/166Ho in vivo generator to deliver 166Ho to the target tissue causes the minimum exposure to the non-target tissues and increased absorbed dose rate in the target tissue compared to other similar radiopharmaceuticals. In this work, theoretical calculations of 166Dy/166Ho in vivo generator production in Tehran Research Reactor were performed through solving the decay chain differential equations simultaneously for natural and enriched dysprosium targets and the obtained results were compared with experimental values. The results showed that there is a good compatibility between the measured values and the results of the theoretical calculations. The outcomes of this study are used to produce 166Dy / 166Ho radionuclide generator.

Keywords

References

[1] E. Dadachova, S. Mirzadeh, R. Lambrecht, E. Hetherington and F. Knapp. Separation of carrier-free166Ho from Dy2O3 targets by partition chromatography and electrophoresis, JRNC, 199(2) (1995) 115–123. [2] R.J. Mumper, U.Y. Ryo and M. Jay. Neutron-Activated Holmium-166-Poly (L-LacticAcid) Microspheres: A Potential Agent for the Internal Radiation Therapy of Hepatic Tumors, J Nucl Med, 32(11) (1991) 2139–2143. [3] J.H. Turner, P.G. Claringbold, P.F. Klemp, P.J. Cameron, A.A. Martindale and R.J Glancy. 166Ho-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig, Nucl Med Commun, 15(7) (1994) 545–53. [4] Manual for reactor produced radioiotopes, IAEA, (2003). [5] Therapeutic applications of radiopharmaceuticals: Proceedings of an international seminar held in Hyderabad, India, (1999) 18-22. [6] S.V. Smith, N.D. Bartolo, S. Mirzadeh, R.M. Lambrecht, Jr.F.F. Knapp and E.L. Hethrington. [166Dy] Dysprosium/[166Ho] Holmium In Vivo Generator, APPI Radiat Hot, 46(8) (1995) 759–764. [7] M.R. Pillai. Metallic Radionuclides and Therapeutic Radiopharmaceuticals, Warszawa, Poland: Institute of Nuclear Chemistry and Technology, (2010). [8] L.F. Mausner, R.F. Straub and S.C. Srivastava. The in vivo generator for radioimmunotherapy, J Label Compd, 26 (117) (1989) 498–500. [9] D. Ma, S.S. Jurisson, G.J. Ehrhardt, W.B. Yelon and A.R. Ketring. Development of the Dy-166/Ho-166 in-vivo generator for radionuclide radiotherapy, 205th ACS national meeting, 26 (1993). [10] S. Mirzadeh, K. Kumar and O.A. Gansow. The Chemical Fate of 212Bi-DOTA Formed by β-Decay of 212Pb (DOTA) 2, Radiochim Acta, 60(1) (1993) 1–10. [11] S. Mirzadeh. ORNL Nuclear Medicine Program Progress Report, ORNL/TM-12159 (1992) 6–11. [12] S. Mirzadeh. ORNL Nuclear Medicine Program Progress Report, ORNL/TM-12485 (1993b) 12–18. [13] Jr.F.F. Knapp and S. Mirzadeh. The continuing important role of radionuclide generator systems for nuclear medicine, Eur J Nucl Med, 21(10) (1994) 1151–1165. [14] R.G. Peyvandi, M. Salehkoutahi, S.S. Arani, A.B. Samani and M.G. Maragheh. Assessment of Radionuclidic Purity of Sm-153 Produced by Irradiation of Natural Samarium in Tehran Research Reactor (TRR), J Nucl Sci Technol, 2(48) (2009) 13–16. [15] S.Z. IslamiRad, M. Shamsaei, R.G Peyvandi, M.G Maragheh, A.B Samani and S.S Arani. Separation of Eu radioisotopes impurity from irradiated natural Sm target for purification of 153Sm, J Nucl Sci Technol, 42(1) (2011) 19–24. [16] S. Vosoughi, S.S Arani and A.B Samani. Production of no-carrier-added Ho-166 for targeted therapy purposes, Iran J Nucl Med, 25(1) (2017) 15–20. [17] S Vosoughi, A.R. Jalilian and S.S Arani. Preparation of 166Dy/166Ho-chitosan as an in vivo generator for radiosynovectomy, J Radioanal Nucl Ch, 311(3) (2017) 1657–64.
Journal of Radiation Safety and Measurement
Volume 9, Issue 6 - Serial Number 35
December 2020
Pages 53-62

Files

Share

How to cite

Statistics